Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
Status:
Terminated
Trial end date:
2021-09-24
Target enrollment:
Participant gender:
Summary
This is a phase 2b prospective, randomized, single-blind, controlled trial of a single
subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2
infection in non-hospitalized participants at high risk for infection due to household
exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate
the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All
participants will be followed for up to 12 weeks.